Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel R Hecht

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
AACE Clinical Case Reports|September 28, 2020
CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORSYingying Yang, Joel R Hecht, Sandy Ting Liu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancerJong-Ho Kim, Johannes Czernin, Martin S Allen-Auerbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
AACE Clinical Case Reports|September 28, 2020
CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORSYingying Yang, Joel R Hecht, Sandy Ting Liu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancerJong-Ho Kim, Johannes Czernin, Martin S Allen-Auerbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Pageof 1